You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,850,473


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,850,473
Title:Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from Streptococcus pneumoniae
Abstract: The present invention provides for recombinant Endo-D and selected mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor by transglycosylation. Such recombinant Endo-D and selected mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain.
Inventor(s): Wang; Lai-Xi (Ellicott City, MD)
Assignee: University of Maryland, Baltimore (Baltimore, MA)
Application Number:14/878,089
Patent Claims:1. A delivery device for delivering a drug having biological activity to treat a condition, the delivery device comprising: a remodeled antibody comprising a recombinant fucosylated antibody having a predetermined number of sugar residues and a drug attached to a terminal sugar, wherein the delivery device is synthesized according to the following steps: a) providing an antibody or fragment thereof comprising a fucosylated N-acetylglucosamine (GlcNAc) acceptor moiety; wherein the fucosylated N-acetylglucosamine (GlcNAc) acceptor moiety is positioned on a Fc region of the antibody or fragment thereof; and b) enzymatically transferring an oligosaccharide moiety having the predetermined number of sugar residues and the drug attached to the terminal sugar of the sugar residues of the oligosaccharide moiety to the fucosylated N-acetylglucosamine (GlcNAc) acceptor moiety under the catalysis of an Endoglycosidase-D full length or truncated mutant selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, to form a modified antibody or fragment thereof with the predetermined number of sugar residues.

2. The delivery device of claim 1, wherein the drug attached to the terminal sugar is a therapeutic agent for treating cancer, a therapeutic agent for HIV, a toxin, an antigen, a therapeutic polypeptide, a chemokine or a cytokine attached to the oligosaccharide.

3. The delivery device of claim 1, wherein the antibody is a monoclonal antibody selected from the group consisting of cetuximab, rituximab, muromonab-CD3, abciximab, daclizumab, basiliximab, palivizumab, infliximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, omalizumab, tositumomab, efalizumab, bevacizumab, panitumumab, pertuzumab, natalizumab, etanercept, volociximab, Anti-CD80 mAb, Anti-CD23 mAb, eraptuzumab, matuzumab, zanolimumab, adecatumumab, oregovomab, nimotuzumab, denosumab, fontolizumab, daclizumab, golimumab, ocrelizumab, HuMax-CD20, belimumab, epratuzumab, visilizumab, tocilizumab, ocrerlizumab, certolizumab pegol, eculizumab, pexelizumab, abciximab, ranibizimumab, and mepolizumab.

4. A delivery device for delivering a drug having biological activity to treat a condition, the delivery device comprising: a remodeled antibody comprising a recombinant fucosylated or nonfucosylated-antibody having a predetermined number of sugar residues and a drug attached to a terminal sugar, wherein the delivery device is synthesized according to the following steps: a) providing an antibody or fragment thereof comprising a fucosylated or nonfucosylated N-acetylglucosamine (GlcNAc) acceptor moiety; wherein the fucosylated or nonfucosylated N-acetylglucosamine (GlcNAc) acceptor moiety is positioned on a Fc region of the antibody or fragment thereof; and b) enzymatically transferring an oligosaccharide moiety having the predetermined number of sugar residues and the drug attached to the terminal sugar of the sugar residues of the oligosaccharide moiety to the fucosylated or nonfucosylated N-acetylglucosamine (GlcNAc) acceptor moiety under the catalysis of an Endoglycosidase-D full length or truncated mutant selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, to form a modified antibody or fragment thereof with the predetermined number of sugar residues, wherein the antibody is a monoclonal antibody selected from the group consisting of cetuximab, rituximab, muromonab-CD3, abciximab, daclizumab, basiliximab, palivizumab, infliximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, omalizumab, tositumomab, efalizumab, bevacizumab, panitumumab, pertuzumab, natalizumab, etanercept, volociximab, Anti-CD80 mAb, Anti-CD23 mAb, eraptuzumab, matuzumab, zanolimumab, adecatumumab, oregovomab, nimotuzumab, denosumab, fontolizumab, daclizumab, golimumab, ocrelizumab, HuMax-CD20, belimumab, epratuzumab, visilizumab, tocilizumab, ocrerlizumab, certolizumab pegol, eculizumab, pexelizumab, abciximab, ranibizimumab, and mepolizumab.

5. The delivery device of claim 4, wherein the drug attached to the terminal sugar is a therapeutic agent for treating cancer, a therapeutic agent for HIV, a toxin, an antigen, a therapeutic polypeptide, a chemokine or a cytokine attached to the oligosaccharide.

Details for Patent 9,850,473

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 12/22/1994 ⤷  Try a Trial 2031-03-03
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2031-03-03
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 05/12/1998 ⤷  Try a Trial 2031-03-03
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 01/02/2003 ⤷  Try a Trial 2031-03-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.